Eli Lilly CEO's Total Compensation Rose 10% in 2024

Dow Jones

03-08

By Connor Hart

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million.

Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments.

Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024.

Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashkenazi received $5 million in total compensation.

Gordon Brooks, who served as interim CFO for a period in 2024, as well as group vice president of corporate strategy and controller, notched $2.7 million in total compensation for the year.

Other executive payouts in 2024 included Chief Scientific Officer Daniel Skovronsky, who received $12.6 million; General Counsel and Secretary Anat Hakim, who received $7.5 million; and President of Loxo@Lilly Jake Van Naarden, who received $5.8 million.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 07, 2025 17:15 ET (22:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517355461"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517355461\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517355461?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-08 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517355461","market":"other","top_or_hot":-1,"title":"Eli Lilly CEO's Total Compensation Rose 10% in 2024","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<p>\n  Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. \n</p>\n<p>\n  Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million. \n</p>\n<p>\n  Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments. \n</p>\n<p>\n  Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024. \n</p>\n<p>\n  Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashkenazi received $5 million in total compensation. \n</p>\n<p>\n  Gordon Brooks, who served as interim CFO for a period in 2024, as well as group vice president of corporate strategy and controller, notched $2.7 million in total compensation for the year. \n</p>\n<p>\n  Other executive payouts in 2024 included Chief Scientific Officer Daniel Skovronsky, who received $12.6 million; General Counsel and Secretary Anat Hakim, who received $7.5 million; and President of Loxo@Lilly Jake Van Naarden, who received $5.8 million. \n</p>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 07, 2025 17:15 ET (22:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Eli Lilly CEO's Total Compensation Rose 10% in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly CEO's Total Compensation Rose 10% in 2024\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-08 06:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<p>\n  Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. \n</p>\n<p>\n  Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million. \n</p>\n<p>\n  Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments. \n</p>\n<p>\n  Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024. \n</p>\n<p>\n  Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashkenazi received $5 million in total compensation. \n</p>\n<p>\n  Gordon Brooks, who served as interim CFO for a period in 2024, as well as group vice president of corporate strategy and controller, notched $2.7 million in total compensation for the year. \n</p>\n<p>\n  Other executive payouts in 2024 included Chief Scientific Officer Daniel Skovronsky, who received $12.6 million; General Counsel and Secretary Anat Hakim, who received $7.5 million; and President of Loxo@Lilly Jake Van Naarden, who received $5.8 million. \n</p>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 07, 2025 17:15 ET (22:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0792757196.USD","symbol_name":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517355461","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517355461","pubTimestamp":1741385700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million.Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments.Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024.Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashke","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2247934214.USD":"FIDELITY FUNDS SUSTAINABLE FUTURE CONNECTIVITY \"A\" (USD) ACC","TSS":"Total System Services","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","BK4573":"虚拟现实","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK4561":"索罗斯持仓","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","LLY":"礼来","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","USJW.SI":"ALPHAB 3xLongSG261006","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BK4585":"ETF&股票定投概念","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4576":"AR","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H"},"translate_title":"礼来公司首席执行官2024年总薪酬增长10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSS":1,"LLY":1,"USJW.SI":0.6},"content_text":"By Connor Hart \n\n\n  Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. \n\n\n  Ricks' payout included $19.7 million in stock awards, $5.7 million in bonuses and nearly $352,000 in other forms of compensation, according to the drugmaker's 2025 proxy statement filed Friday with the Securities and Exchange Commission. His base salary for the year was $1.7 million. \n\n\n  Bonuses were tied to performance. Eli Lilly said that executives' performance highlights last year included delivering a strong financial performance, with product revenue and earnings per share topping internal targets, as well as furthering its pipeline of treatments. \n\n\n  Lucas Montarce, who was appointed as Eli Lilly's top finance chief in September, received $2.9 million in total compensation in 2024. \n\n\n  Montarce succeeded Anat Ashkenazi, who left the company earlier in the year to become CFO of Google-parent Alphabet. For her work with Eli Lilly in 2024, Ashkenazi received $5 million in total compensation. \n\n\n  Gordon Brooks, who served as interim CFO for a period in 2024, as well as group vice president of corporate strategy and controller, notched $2.7 million in total compensation for the year. \n\n\n  Other executive payouts in 2024 included Chief Scientific Officer Daniel Skovronsky, who received $12.6 million; General Counsel and Secretary Anat Hakim, who received $7.5 million; and President of Loxo@Lilly Jake Van Naarden, who received $5.8 million. \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 17:15 ET (22:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0}}}